Q1 2026 saw operational and financial pressures, with revenue hit by medication shortages and a one-time spike in doubtful accounts provisioning. Cost controls and capital discipline are underway, but leverage increased and cash flow was negative.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.